US Patent Issued to GlaxoSmithKline Intellectual Property (No. 3) on Dec. 2 for "Treatment with P2X3 modulators" (Canadian Inventors)

ALEXANDRIA, Va., Dec. 2 -- United States Patent no. 12,485,125, issued on Dec. 2, was assigned to GlaxoSmithKline Intellectual Property (No. 3) Ltd. (Stevenage, Great Britain).

"Treatment with P2X3 modulators" was invented by Antonios Matzouranis (Laval, Canada), Denis Garceau (Laval, Canada) and Roberto Bellini (Laval, Canada).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are methods for treating endometriosis, endometriosis-associated pain, and endometriosis-associated symptoms in a mammal in need thereof with a P2X3 modulator."

The patent was filed on Aug. 30, 2021, under Application No. 17/461,988.

*For further information, including images, charts and tables, please visit: http://patft...